Adagrasib (Krazati)

On December 12, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to adagrasib for the treatment of adult patients with KRASG12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.1